5 INDICATIONS

Prolia® is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Prolia® reduces the incidence of vertebral, See More

You are now leaving ProliaHCP.com

You are now leaving ProliaHCP.com. Please know that the sponsors of this site are not responsible for content on the site you are about to enter.

Please to continue.

Prolia® Mechanism of Action

Suggested Resources:

Mechanism of Action Video

ProliaFinder.com

Billing and Coding Guide

See More Downloads, Websites, and Videos

Suggested Pages:

Starting Patients

Safety & Efficacy (up to 10 Years)

Buy & Bill Resources

95% of Medicare Part D patients have access* to Prolia®1

Nearly 8 out of 10 of Medicare Part D patients require

  • No step edit1,†
  • No prior authorization1,†
The average out-of-pocket (OOP) cost for Prolia® through Medicare Part D is $257‡ every 6 months, which equals $42.91 per month.1,§
Prescription pad

For your pharmacy patients: Some Medicare Part D plans have a preferred specialty pharmacy and some commercial plans require a specific specialty pharmacy for filling a patient’s Prolia® prescription.**

For patients with limited income: Medicare beneficiaries may qualify for Extra Help, a program to help pay for medication costs through Medicare Part D.2 Visit the Medicare website to learn more about Extra Help.

Dual eligible patients: Medicare Part D is the primary source of drug coverage for “dual eligible” beneficiaries covered under both Medicare and Medicaid.3

*Access is defined as the ability of a patient to obtain Prolia®, although patient OOP cost and insurance requirements may vary.

†All Pharmacy Lives associated with Medicare Part D coverage Restriction for Prolia® in DRG Coverage data snapshot as of June 2022 are included in this analysis.

‡Individual OOP costs may vary based on phases of Part D coverage.

§All patients who had a Prolia® Medicare Part D claim from September 2021 to August 2022 through Retail Medicare Part D channels are included in the analysis.

**The information is provided as a courtesy only and Amgen does not guarantee the accuracy of the information.

Essential Downloads for Your Office

Download

Coding and Billing Information Guide
Download

5-Step Guide to Buy and Bill

View All Resources
  • Medicare Part D plans may have a preferred specialty pharmacy network
  • Commercial plans may require a specific specialty pharmacy

Consult your patient's health plan or Medicare contractor to confirm the appropriate specialty pharmacy for filling Prolia® prescriptions.

MEDICAL AND/OR PRESCRIPTION PLAN
Aetna
Express Scripts
Cigna
CVS/Caremark
Highmark
Humana
PREFERRED NETWORK
CVS Specialty
Accredo Health Group
Accredo Health Group
CVS Specialty
Accredo Health Group
CenterWell Specialty Pharmacy

The pharmacies listed above are for information purposes only and may not be comprehensive of all available mandated specialty pharmacies for a particular plan. The information provided is not a guarantee of fulfillment. Information as of 9/30/2021. For the most up-to-date and complete information, please refer to a patient’s health plan regarding specific policies, instructions, and requirements.

Amgen® SupportPlus

We’re right here, right when you need us. Personalized support that you and your parents can count on across Amgen therapies

Benefit Verification

Benefit Verification

Amgen® SupportPlus can verify patient’s insurance plan coverage details. Visit myAmgenPortal.com to register and submit forms online or fax completed Insurance Verification Form to 1-877-877-6542.

icon_Link_Out_default

VISIT AMGEN SUPPORTPLUS CUSTOMER PORTAL

DOWNLOAD PROLIA® INSURANCE VERIFICATION FORM

Financial Support

Financial Support

We know every patient has unique needs. And we're here to provide financial support information and resources, regardless of their current financial situation or type of insurance they have.
Learn more about how Amgen® SupportPlus can help your patients access their prescribed medication.
Visit AmgenSupportPlus.com to learn more.

Referrals to Alternate
Sites of Care

Referrals to Alternate Sites of Care

Search for alternate sites of care and pharmacies with Prolia® Finder™ to help your patients get their Prolia® treatment.

IMPORTANT SAFETY INFORMATION

SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE:

Patients with advanced chronic kidney disease are at greater risk of severe hypocalcemia following Prolia administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported. The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia. Prior to initiating Prolia in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Prolia in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD.

Contraindications: Prolia® is contraindicated in patients with hypocalcemia. Pre-existing hypocalcemia must be corrected prior to initiating Prolia®. Prolia® is contraindicated in women who are pregnant and may cause fetal harm. In women of reproductive potential, pregnancy testing should be performed prior to initiating treatment with Prolia®. Prolia® is contraindicated in patients with a history of systemic hypersensitivity to any component of the product. Reactions have included anaphylaxis, facial swelling and urticaria.

Severe Hypocalcemia and Mineral Metabolism Changes: Prolia can cause severe hypocalcemia and fatal cases have been reported. Pre existing hypocalcemia must be corrected prior to initiating therapy with Prolia. Adequately supplement all patients with calcium and vitamin D.

In patients without advanced chronic kidney disease who are predisposed to hypocalcemia and disturbances of mineral metabolism (e.g. treatment with other calcium lowering drugs), assess serum calcium and mineral levels (phosphorus and magnesium) 10 to14 days after Prolia injection.

Same Active Ingredient: Prolia® contains the same active ingredient (denosumab) found in XGEVA®. Patients receiving Prolia® should not receive XGEVA®.

Hypersensitivity: Clinically significant hypersensitivity including anaphylaxis has been reported with Prolia®. Symptoms have included hypotension, dyspnea, throat tightness, facial and upper airway edema, pruritus and urticaria. If an anaphylactic or other clinically significant allergic reaction occurs, initiate appropriate therapy and discontinue further use of Prolia®.

Osteonecrosis of the Jaw (ONJ): ONJ, which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients receiving Prolia®. An oral exam should be performed by the prescriber prior to initiation of Prolia®. A dental examination with appropriate preventive dentistry is recommended prior to treatment in patients with risk factors for ONJ such as invasive dental procedures, diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders. Good oral hygiene practices should be maintained during treatment with Prolia®. The risk of ONJ may increase with duration of exposure to Prolia®.

For patients requiring invasive dental procedures, clinical judgment should guide the management plan of each patient. Patients who are suspected of having or who develop ONJ should receive care by a dentist or an oral surgeon. Extensive dental surgery to treat ONJ may exacerbate the condition. Discontinuation of Prolia® should be considered based on individual benefit-risk assessment.

Atypical Femoral Fractures: Atypical low-energy, or low trauma fractures of the shaft have been reported in patients receiving Prolia®. Causality has not been established as these fractures also occur in osteoporotic patients who have not been treated with antiresorptive agents.

During Prolia® treatment, patients should be advised to report new or unusual thigh, hip, or groin pain. Any patient who presents with thigh or groin pain should be evaluated to rule out an incomplete femur fracture. Interruption of Prolia® therapy should be considered, pending a risk/benefit assessment, on an individual basis.

Multiple Vertebral Fractures (MVF) Following Discontinuation of Prolia® Treatment: Following discontinuation of Prolia® treatment, fracture risk increases, including the risk of multiple vertebral fractures. New vertebral fractures occurred as early as 7 months (on average 19 months) after the last dose of Prolia®. Prior vertebral fracture was a predictor of multiple vertebral fractures after Prolia® discontinuation. Evaluate an individual’s benefit/risk before initiating treatment with Prolia®. If Prolia® treatment is discontinued, consider transitioning to an alternative antiresorptive therapy.

Serious Infections: In a clinical trial (N=7808), serious infections leading to hospitalization were reported more frequently in the Prolia® group than in the placebo group. Serious skin infections, as well as infections of the abdomen, urinary tract and ear were more frequent in patients treated with Prolia®.

Endocarditis was also reported more frequently in Prolia®-treated patients. The incidence of opportunistic infections and the overall incidence of infections were similar between the treatment groups. Advise patients to seek prompt medical attention if they develop signs or symptoms of severe infection, including cellulitis.

Patients on concomitant immunosuppressant agents or with impaired immune systems may be at increased risk for serious infections. In patients who develop serious infections while on Prolia®, prescribers should assess the need for continued Prolia® therapy.

Dermatologic Adverse Reactions: Epidermal and dermal adverse events such as dermatitis, eczema and rashes occurred at a significantly higher rate with Prolia® compared to placebo. Most of these events were not specific to the injection site. Consider discontinuing Prolia® if severe symptoms develop.

Musculoskeletal Pain: Severe and occasionally incapacitating bone, joint, and/or muscle pain has been reported in patients taking Prolia®. Consider discontinuing use if severe symptoms develop.

Suppression of Bone Turnover: Prolia® resulted in significant suppression of bone remodeling as evidenced by markers of bone turnover and bone histomorphometry. The significance of these findings and the effect of long-term treatment are unknown. Monitor patients for consequences, including ONJ, atypical fractures, and delayed fracture healing.

Adverse Reactions: The most common adverse reactions (>5% and more common than placebo) in women with postmenopausal osteoporosis are back pain, pain in extremity, musculoskeletal pain, hypercholesterolemia, and cystitis. The most common adverse reactions (>5% and more common than placebo) in men with osteoporosis are back pain, arthralgia, and nasopharyngitis. Pancreatitis has been reported with Prolia®.

In women with postmenopausal osteoporosis, the overall incidence of new malignancies was 4.3% in the placebo group and 4.8% in the Prolia® group. In men with osteoporosis, new malignancies were reported in no patients in the placebo group and 4 (3.3%) patients in the Prolia® group. A causal relationship to drug exposure has not been established.

The most common adverse reactions (>3% and more common than active-control group) in patients with glucocorticoid-induced osteoporosis are back pain, hypertension, bronchitis, and headache.

The most common (per patient incidence 10%) adverse reactions reported with Prolia® in patients with bone loss receiving ADT for prostate cancer or adjuvant AI therapy for breast cancer are arthralgia and back pain. Pain in extremity and musculoskeletal pain have also been reported in clinical trials. Additionally, in Prolia®-treated men with nonmetastatic prostate cancer receiving ADT, a greater incidence of cataracts was observed.

Denosumab is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity.

Please see Prolia® full Prescribing Information, including Medication Guide.

IMPORTANT SAFETY INFORMATION
SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE: Patients with advanced chronic kidney disease are at greater risk of severe hypocalcemia following Prolia administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported. The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia. Prior to initiating
Back to Top

References: 1. Data on file, Amgen; 2022. 2. Medicare.gov website. Find your level of Extra Help (Part D). https://www.medicare.gov/your-medicare-costs/get-help-paying-costs/find-your-level-of-extra-help-part-d. Accessed September 22, 2023. 3. CRSreports.congress.gov website. Medicare Part D prescription drug benefit. https://crsreports.congress.gov/product/pdf/R/R40611. Accessed September 22, 2023.